Detalles de la búsqueda
1.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet;
396(10267): 1994-2005, 2021 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33308425
2.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav;
24(12): 3533-3544, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32447500
3.
Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons: a French survey in infectious diseases departments in Paris.
AIDS Care;
32(7): 811-817, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31431047
4.
Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4).
Clin Infect Dis;
67(2): 275-282, 2018 07 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29635465
5.
Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Clin Infect Dis;
60(10): 1521-7, 2015 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25690598
6.
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
Lancet;
383(9936): 2222-31, 2014 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-24698485
7.
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Open Forum Infect Dis;
8(9): ofab439, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34557563
8.
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr;
85(3): 325-330, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32675772
9.
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Lancet HIV;
6(9): e576-e587, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31307948
10.
Amniocentesis in pregnant HIV-infected patients. Absence of mother-to-child viral transmission in a series of selected patients.
Eur J Obstet Gynecol Reprod Biol;
140(2): 212-7, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18584937
11.
Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France.
PLoS One;
13(10): e0205385, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30379870
12.
Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.
AIDS;
30(14): 2235-46, 2016 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27428741
13.
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
J Acquir Immune Defic Syndr;
70(5): 515-9, 2015 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26262777
14.
Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.
PLoS One;
10(3): e0118492, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25734445
15.
Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).
Int J Epidemiol;
43(5): 1425-36, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24550249
16.
Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women.
HIV Clin Trials;
8(4): 254-5, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17720666
17.
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
J Acquir Immune Defic Syndr;
55(1): 49-57, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20431394
Resultados
1 -
17
de 17
1
Próxima >
>>